Capricor Therapeutics, Inc. (NASDAQ:CAPR) belongs to Healthcare sector. Its weekly performance is -2.50%. On last trading day company shares ended up $4.68. Capricor Therapeutics, Inc. (NASDAQ:CAPR) distance from 50-day simple moving average (SMA50) is -22.39%. On 17 June, Capricor Therapeutics, Inc. (NASDAQ:CAPR) announced the appointment of Houman Hemmati, M.D., Ph.D. to the newly created position of Vice President of Medical and Clinical Development for New Therapies. In this role, Dr. Hemmati will work to drive promising new therapies such as Capricor’s exosome platform into clinical development as he works closely with the R&D, manufacturing and product development teams.
NanoView Biosciences Launches EPIC Study to Investigate Impact of Exosome-Associated Biomarkers for Immuno-Oncology
1 day ago
Organicell and Oklahoma State University Enter Into Agreement To Study Zofin™ in Respiratory Diseases Caused By Virus Infections Of Pandemic Potential
6 days ago